Natural killer cells for hard-to-treat neuroblastoma
Part of Cancer clinical trials.
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 39 years old
- You must have neuroblastoma that has come back or stopped responding to standard chemotherapy
- Your cancer must be classified as high-risk or have become high-risk over time
- You must have a partially matched family donor (parent, sibling, or other close relative) available
- Your heart, lungs, blood counts, and kidneys must be working well enough (specific measurements required)
- You cannot have an active, uncontrolled infection or have received a live vaccine in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests a new type of immunotherapy using natural killer cells (immune cells that fight cancer) given after a stem cell transplant in children with leukemia or neuroblastoma. The goal is to see if these cells help prevent cancer from coming back and are safe for young patients.
This trial tests whether combining your child's own immune cells (NK cells) with a targeted antibody (GD2) can help treat high-risk neuroblastoma. It is for children who are in the maintenance phase, or whose cancer has returned or not responded to standard treatment.
This trial tests a modified version of your own immune cells (made from your blood) to help treat advanced cancers that are no longer responding to standard treatment. It’s designed mainly to see if the approach is safe and how well it may work for people whose disease has progressed.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.